<- Go home

Added to YB: 2025-12-30

Pitch date: 2025-12-29

PRPO [bullish]

Precipio, Inc.

Author Info

No bio for this author

Company Info

Precipio, Inc., a healthcare biotechnology company, provides cancer diagnostic products, reagents, and services in the United States.

Market Cap

$41.6M

Pitch Price

N/A

Price Target

N/A

Dividend

N/A

EV/EBITDA

-88.42

P/E

-29.12

EV/Sales

1.88

Sector

Health Care Providers and Services

Category

growth

Show full summary:
The portfolio I am taking into 2026 - Precipio, Inc.

PRPO: US blood cancer diagnostics w/ proprietary HemeScreen (14→2 day test time) & IV-Cell tech. 30%+ growth, near break-even, OPEX flat going forward. 15-20% topline growth, gross margins 45%→60% from mix shift. 2027: 11x PE, 1.2x EV/Sales. Est 40%+ annual returns next 4-5 years.

Read full article (1 min)